HealthRX Reviews: The $161 Is Real, and That's Rare

The one-sentence version

HealthRX advertises NAD+ injection at $161/mo, and $161 is what a month-to-month buyer is actually charged — a sentence we have not been able to write about most of this board. The multi-month plans go down from there rather than the headline being the bottom rung dressed up as a monthly price. It grades A, 14 out of 14, tied for the highest score on our rankings, and the grade is computed from published terms alone and cannot see who pays us.

What it is, and who it's for

HealthRX is a LegitScript-certified compounded telehealth practice (CERT 50087439) with a longevity shelf rather than a single hero product: NAD+ as an injection or a nasal spray, plus sermorelin, rapamycin, metformin, methylene blue, low-dose naltrexone, glutathione, enclomiphene and testosterone. Every one carries a published monthly figure on the shop page. Shipping is "free overnight… all 50 states."

The buyer this suits wants a compounded protocol at a number they can read before entering a card, with no membership, no lab gate and no consultation fee. If you want bloodwork attached to the protocol, this is not that — see longevity biomarker panels for what a monitored program looks like instead.

What it actually costs

All figures verified on healthrx.com on 26 July 2026.

The subscribe rate is the monthly rate. NAD+ injection $161/mo billed monthly; nasal spray $134/mo billed monthly. Both auto-renew, and the page states "pause or cancel anytime."

The one-time price is published too. A "One-time" tab sits beside "Subscribe" on every product page: $179 for the injection, $149 for the nasal spray. Subscribing takes 10% off — "Save 10% today and on every refill." So the advertised figure does require auto-refill, but the alternative is displayed rather than hidden, and the gap is 11%, not the 18–20% we have found elsewhere.

The longer cadences go down, not up. On the injection: every 3 months $145/mo ($434 total, save 10%), every 6 months $137/mo ($821, 15%), every 12 months $129/mo ($1,546, 20%). On the nasal spray: $120, $114 and $107 respectively.

The catalogue label is "SUBSCRIBE FROM $161/mo" — and $161 is the dearest subscribe rung. "From" is doing the opposite of what it does everywhere else in this category, where a "from" price is invariably the twelve-month prepay. Read literally it is loose wording; read commercially it errs in the buyer's favour, which is why it costs HealthRX a sentence here rather than a rubric point.

What's inside the figure. "Medication and supplies," "Provider visit and unlimited follow-ups," "Free expedited shipping," and an injection home kit. No membership, no lab requirement, no separate consultation fee. The injection is 1,000 mg per month; the nasal spray is a 15 mL bottle at 300 mg/mL, with "strength set by your provider."

If you are declined, you are not billed. "If your provider decides NAD+ injection isn't clinically appropriate for you, you won't be charged for the medication." Note the wording covers the medication specifically — there is no separate consult fee here to argue about, which is the point. On how these figures sit against clinic pricing generally, see what longevity care costs.

Clinical oversight and the pharmacy

Prescriptions follow a review by "an independent US Board-certified physician," and follow-ups are unlimited rather than metered. Our grading methodology weights that at two points, and HealthRX takes them.

On pharmacy it states the standard and not the facility: "filled by a licensed Section 503A compounding pharmacy," with a "COMPOUNDED BY A LICENSED 503A PHARMACY" badge in the global footer and the full sentence in the product-page disclaimer. Stating the section earns the top rung of our pharmacy factor, but treat it as a legal category rather than a quality certification: 503A compounders are specifically not subject to current good manufacturing practice requirements, unlike 503B outsourcing facilities, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed¹. Which pharmacy actually fills your prescription is not disclosed.

The evidence behind what it sells

This is the section where most of this board embarrasses itself, and HealthRX does not. Its own product page says NAD+ injection "is not FDA-approved for any use," that "the most relevant human study is a single 50-person, eight-week pilot that measured safety, not whether the injection produces any specific wellness or performance benefit," and — remarkably — that "we don't have solid human data on downstream effects like energy, fatigue, cognition, or aging markers, and we won't claim benefits the evidence doesn't yet support." It discloses side-effect rates from that pilot: nausea about 22%, injection-site reactions about 18%, flushing, chest tightness on rapid infusion.

The independent record agrees with them. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific" with clinical effectiveness "inconclusive," and reported that no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all². A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time³. The strongest randomised trial in the field moved six-minute walk distance about 17.6 metres in peripheral artery disease — a disease endpoint, not an aging one⁴. See NAD+ for longevity, do NAD+ peptides actually work and what's proven versus hyped.

Where it's weak, and who should skip it

Two real gaps. The pharmacy is not named, so you know the standard and not the facility. And the nasal spray is the weaker buy at $134/mo: HealthRX itself says the route "hasn't been measured in human studies at all; its human bioavailability is currently unknown." Paying $1,608 a year for an unmeasured route is a decision the page gives you enough information to refuse, which is to its credit, but it is still the decision.

Skip it entirely if you want anything measured — there is no bloodwork here, before or after, so nothing in the program can tell you whether the protocol did anything.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). HealthRX takes all five. The whole ladder is published for both routes with the billing cadence beside each rung and the one-time alternative shown; the longevity line is a real shelf rather than a GLP-1 shop with an NAD+ add-on; the provider visit and unlimited follow-ups sit inside the price; and it states its compounding section on a surface it controls. Fourteen out of fourteen. An A.

The complaint is that it will not name the pharmacy, and that the cheapest rungs are still prepays. What it does not do is the thing that costs everyone else on this board points: it does not advertise a number nobody pays. The full graded field is at our provider rankings; the two rows either side of it are our CoreAge Rx review and Direct Meds review.